Literature DB >> 7639799

Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis.

P Chomarat1, J Banchereau, P Miossec.   

Abstract

OBJECTIVE: To determine how the antiinflammatory cytokines interleukin-10 (IL-10) and IL-4 affect the production of IL-6 in rheumatoid arthritis (RA) and to assess the contribution of IL-10 production.
METHODS: IL-6 production was measured by enzyme-linked immunosorbent assay (ELISA) in the supernatants of cultured RA synovium pieces (from 23 patients), purified RA synovial tissue monocyte/macrophages, and RA blood monocytes, in the presence of IL-10 and IL-4. IL-10 was also detected by ELISA in culture supernatants and in RA sera.
RESULTS: The production of IL-6 by RA synovium was strongly inhibited by IL-4 (46.6%; P = 0.0001) and was inhibited to a lower extent by IL-10 (25.3%; P = 0.03). Likewise, the spontaneous production of IL-6 by RA synovial tissue monocyte/macrophages was decreased by the addition of IL-4 (48.8%) and IL-10 (23.7%). This inhibition of IL-6 production was significantly lower (P < 0.03) than that observed with RA blood monocytes (83.0% for IL-10 and 85.2% for IL-4). Interestingly, and in contrast to RA blood monocytes, RA synovial tissue monocyte/macrophages produced spontaneously high levels of IL-10, which were inhibited by IL-4 and interferon-gamma.
CONCLUSION: The ability of IL-10 and IL-4 to suppress IL-6 production was dependent on 1) differences in the state of differentiation of blood and synovial tissue monocytes, and 2) local production of cytokine inside the synovium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639799     DOI: 10.1002/art.1780380805

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis.

Authors:  A Kawakami; K Eguchi; N Matsuoka; M Tsuboi; S Urayama; Y Kawabe; T Aoyagi; K Maeda; S Nagataki
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

3.  IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE).

Authors:  B Bussolati; C Rollino; F Mariano; F Quarello; G Camussi
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

4.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

5.  An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis.

Authors:  Heiner Appel; Lucia Neure; Maren Kuhne; Jürgen Braun; Martin Rudwaleit; Joachim Sieper
Journal:  Clin Rheumatol       Date:  2004-07-28       Impact factor: 2.980

6.  Ganoderma lucidum polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast.

Authors:  Y W Ho; J S L Yeung; P K Y Chiu; W M Tang; Z B Lin; R Y K Man; C S Lau
Journal:  Mol Cell Biochem       Date:  2007-01-12       Impact factor: 3.842

Review 7.  Macrophages in rheumatoid arthritis.

Authors:  R W Kinne; R Bräuer; B Stuhlmüller; E Palombo-Kinne; G R Burmester
Journal:  Arthritis Res       Date:  2000-04-12

Review 8.  Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis.

Authors:  Milena Iwaszko; Sylwia Biały; Katarzyna Bogunia-Kubik
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

9.  IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10.

Authors:  C Steen-Louws; S A Y Hartgring; J Popov-Celeketic; A P Lopes; M B M de Smet; N Eijkelkamp; F P J G Lafeber; C E Hack; J A G van Roon
Journal:  Clin Exp Immunol       Date:  2018-11-11       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.